Dimension	Included	Excluded
Population	Recipients of CAR T-cell or CD3-engaging bispecific-antibody therapy	Other therapies or populations without relevant immune effector exposure
Intervention/exposure	CAR T-cell therapy; CD3-engaging bispecific antibodies	Preclinical exposure without directly applicable clinical findings
Comparator	Not required	Not applicable
Outcomes	ICANS recognition/grading; serial monitoring; EEG/imaging; timing; neurologic management/mitigation; outpatient workflows; delayed BCMA syndromes	No ICANS or extractable clinically relevant neurologic outcome
Study type	Consensus guidance, reviews, meta-analyses, trials, observational studies, real-world cohorts, pilots, clinically informative case reports	Conference abstracts, editorials, commentaries, preprints, non-peer-reviewed reports, overlapping reports without additional findings
Language	English	Non-English